Poseida Therapeutics, Inc.
http://poseida.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Poseida Therapeutics, Inc.
Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.
CAR-T Safety Probe Causes Alarm, But Is Unlikely To Upend Therapies
Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.
Finance Watch: Sage Warns Of Job Cuts, Joins Peers Making Cash Last After Setbacks
Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.
Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem
More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Transposagen Biopharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice